Dysregulation of maternal immunity during pregnancy by pregravid obesity
Project Number3R01AI145910-06S1
Contact PI/Project LeaderMESSAOUDI, ILHEM
Awardee OrganizationUNIVERSITY OF KENTUCKY
Description
Abstract Text
Successful pregnancy requires carefully coordinated changes in the immune system that facilitate placentation,
promote fetal tolerance and growth, and induce labor. Deviations from this tightly regulated “pregnancy
immunological clock” can lead to as pre-eclampsia and complications during labor. The rates of obesity amongst
women of childbearing age have increased at an alarming rate, making it one of the most common comorbidities
during pregnancy. Previously published studies and our preliminary data indicate an enhancement of monocyte
response to LPS between 12 and 37 weeks of gestation Importantly, our preliminary analyses indicate that
maternal pregravid body mass index (BMI) >30 abrogates this pregnancy-associated monocyte activation. This
observation provides a potential explanation for the increased susceptibility to infections and poor wound healing
outcomes observed in obese pregnant women. We hypothesize that chronic low grade inflammation
induced by pregravid obesity disrupts the gestational age dependent monocyte activation, skewing them
to an immunotolerant phenotype. Additionally, given that macrophages in the decidua are recruited from
circulating monocytes, we will investigate the burden of obesity on phenotype and function of decidual
macrophages. We further hypothesize that pregravid obesity results in a hyper-inflammatory phenotype
within decidual macrophages. We will employ a multi-dimensional approach to test these hypotheses. The
novelty of this application lies in the systems biology approach that integrates phenotypic, functional, and
genomic readouts longitudinally in peripheral blood and at term in the placenta. Completion of the proposed
experiments will reveal the molecular mechanisms that explain progressive changes in monocyte activation over
the course of healthy pregnancy, and how that is disrupted with obesity.
Public Health Relevance Statement
NARRATIVE
Pre-pregnancy obesity is associated with significant adverse health outcomes for the mother including increased
risk of gestational diabetes and hypertension, preeclampsia and infection. Recent studies from our laboratory
revealed significant changes in immune cell function in blood samples collected from obese women at week 37
of gestation. Since immune cells play a critical role in anti-microbial defense as well as the development of
chronic inflammation, this application will carry out an in-depth investigation of maternal pre-pregnancy obesity-
driven changes in the functional, transcriptional, and epigenetic landscape of blood immune cells.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
939017877
UEI
H1HYA8Z1NTM5
Project Start Date
01-September-2019
Project End Date
31-August-2025
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$440,401
Direct Costs
$287,844
Indirect Costs
$152,557
Year
Funding IC
FY Total Cost by IC
2024
National Institute on Drug Abuse
$440,401
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3R01AI145910-06S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R01AI145910-06S1
Patents
No Patents information available for 3R01AI145910-06S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R01AI145910-06S1
Clinical Studies
No Clinical Studies information available for 3R01AI145910-06S1
News and More
Related News Releases
No news release information available for 3R01AI145910-06S1
History
No Historical information available for 3R01AI145910-06S1
Similar Projects
No Similar Projects information available for 3R01AI145910-06S1